Treatment resistant schizophrenia and response to antipsychotics: A review

Takefumi Suzuki, Gary Remington, Benoit H. Mulsant, Tarek K. Rajji, Hiroyuki Uchida, Ariel Graff-Guerrero, David C. Mamo

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background: There remains a lack of agreement regarding criteria for treatment-resistant schizophrenia (TRS) and definition of response. Method: A literature search was conducted to identify clinical studies of antipsychotics in TRS using PubMed, EMBASE and PsycINFO (last search 31 July 2011). Psychopharmacological studies with the number of participants of ≥ 40 were evaluated in terms of definitions for TRS and subsequent treatment response. Results: Thirty-three studies of antipsychotics in TRS were reviewed. TRS has been defined mainly by severity in symptoms. Many studies based TRS with at least 2 failed adequate antipsychotic trials (at chlorpromazine equivalent doses of ≥ 1000. mg/day for ≥ 6. weeks), but some studies adopted prospective treatment arm to be certain of sample refractoriness. Treatment response has been defined by a relative change in the representative scales (most commonly ≥ 20% decrease in the Positive and Negative Syndrome Scale), but it sometimes included the absolute criteria such as post-treatment score of ≤ 35 in the Brief Psychiatric Rating Scale or Clinical Global Impression-severity score of ≤ 3 (mild or less severe). Social functioning has not been a primary outcome measure in past pivotal trials, and other important domains of the illness such as cognition and subjective perspectives have not been incorporated into definitions of treatment resistance or response. However, adopting various assessment scales can be time-consuming and complicated, with an additional possibility of disagreement among raters. Conclusion: Defining outcomes in schizophrenia is a challenging task. It is imperative that the field agrees on how this population is better defined and what constitutes treatment response.

Original languageEnglish
Pages (from-to)54-62
Number of pages9
JournalSchizophrenia Research
Volume133
Issue number1-3
DOIs
Publication statusPublished - 2011 Dec

Fingerprint

Antipsychotic Agents
Schizophrenia
Therapeutics
Brief Psychiatric Rating Scale
Chlorpromazine
PubMed
Cognition
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • Definition
  • Response
  • Treatment-resistant schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Suzuki, T., Remington, G., Mulsant, B. H., Rajji, T. K., Uchida, H., Graff-Guerrero, A., & Mamo, D. C. (2011). Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophrenia Research, 133(1-3), 54-62. https://doi.org/10.1016/j.schres.2011.09.016

Treatment resistant schizophrenia and response to antipsychotics : A review. / Suzuki, Takefumi; Remington, Gary; Mulsant, Benoit H.; Rajji, Tarek K.; Uchida, Hiroyuki; Graff-Guerrero, Ariel; Mamo, David C.

In: Schizophrenia Research, Vol. 133, No. 1-3, 12.2011, p. 54-62.

Research output: Contribution to journalArticle

Suzuki, T, Remington, G, Mulsant, BH, Rajji, TK, Uchida, H, Graff-Guerrero, A & Mamo, DC 2011, 'Treatment resistant schizophrenia and response to antipsychotics: A review', Schizophrenia Research, vol. 133, no. 1-3, pp. 54-62. https://doi.org/10.1016/j.schres.2011.09.016
Suzuki, Takefumi ; Remington, Gary ; Mulsant, Benoit H. ; Rajji, Tarek K. ; Uchida, Hiroyuki ; Graff-Guerrero, Ariel ; Mamo, David C. / Treatment resistant schizophrenia and response to antipsychotics : A review. In: Schizophrenia Research. 2011 ; Vol. 133, No. 1-3. pp. 54-62.
@article{b704f7d07c8e4f3b8969dd8d1819a34f,
title = "Treatment resistant schizophrenia and response to antipsychotics: A review",
abstract = "Background: There remains a lack of agreement regarding criteria for treatment-resistant schizophrenia (TRS) and definition of response. Method: A literature search was conducted to identify clinical studies of antipsychotics in TRS using PubMed, EMBASE and PsycINFO (last search 31 July 2011). Psychopharmacological studies with the number of participants of ≥ 40 were evaluated in terms of definitions for TRS and subsequent treatment response. Results: Thirty-three studies of antipsychotics in TRS were reviewed. TRS has been defined mainly by severity in symptoms. Many studies based TRS with at least 2 failed adequate antipsychotic trials (at chlorpromazine equivalent doses of ≥ 1000. mg/day for ≥ 6. weeks), but some studies adopted prospective treatment arm to be certain of sample refractoriness. Treatment response has been defined by a relative change in the representative scales (most commonly ≥ 20{\%} decrease in the Positive and Negative Syndrome Scale), but it sometimes included the absolute criteria such as post-treatment score of ≤ 35 in the Brief Psychiatric Rating Scale or Clinical Global Impression-severity score of ≤ 3 (mild or less severe). Social functioning has not been a primary outcome measure in past pivotal trials, and other important domains of the illness such as cognition and subjective perspectives have not been incorporated into definitions of treatment resistance or response. However, adopting various assessment scales can be time-consuming and complicated, with an additional possibility of disagreement among raters. Conclusion: Defining outcomes in schizophrenia is a challenging task. It is imperative that the field agrees on how this population is better defined and what constitutes treatment response.",
keywords = "Definition, Response, Treatment-resistant schizophrenia",
author = "Takefumi Suzuki and Gary Remington and Mulsant, {Benoit H.} and Rajji, {Tarek K.} and Hiroyuki Uchida and Ariel Graff-Guerrero and Mamo, {David C.}",
year = "2011",
month = "12",
doi = "10.1016/j.schres.2011.09.016",
language = "English",
volume = "133",
pages = "54--62",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Treatment resistant schizophrenia and response to antipsychotics

T2 - A review

AU - Suzuki, Takefumi

AU - Remington, Gary

AU - Mulsant, Benoit H.

AU - Rajji, Tarek K.

AU - Uchida, Hiroyuki

AU - Graff-Guerrero, Ariel

AU - Mamo, David C.

PY - 2011/12

Y1 - 2011/12

N2 - Background: There remains a lack of agreement regarding criteria for treatment-resistant schizophrenia (TRS) and definition of response. Method: A literature search was conducted to identify clinical studies of antipsychotics in TRS using PubMed, EMBASE and PsycINFO (last search 31 July 2011). Psychopharmacological studies with the number of participants of ≥ 40 were evaluated in terms of definitions for TRS and subsequent treatment response. Results: Thirty-three studies of antipsychotics in TRS were reviewed. TRS has been defined mainly by severity in symptoms. Many studies based TRS with at least 2 failed adequate antipsychotic trials (at chlorpromazine equivalent doses of ≥ 1000. mg/day for ≥ 6. weeks), but some studies adopted prospective treatment arm to be certain of sample refractoriness. Treatment response has been defined by a relative change in the representative scales (most commonly ≥ 20% decrease in the Positive and Negative Syndrome Scale), but it sometimes included the absolute criteria such as post-treatment score of ≤ 35 in the Brief Psychiatric Rating Scale or Clinical Global Impression-severity score of ≤ 3 (mild or less severe). Social functioning has not been a primary outcome measure in past pivotal trials, and other important domains of the illness such as cognition and subjective perspectives have not been incorporated into definitions of treatment resistance or response. However, adopting various assessment scales can be time-consuming and complicated, with an additional possibility of disagreement among raters. Conclusion: Defining outcomes in schizophrenia is a challenging task. It is imperative that the field agrees on how this population is better defined and what constitutes treatment response.

AB - Background: There remains a lack of agreement regarding criteria for treatment-resistant schizophrenia (TRS) and definition of response. Method: A literature search was conducted to identify clinical studies of antipsychotics in TRS using PubMed, EMBASE and PsycINFO (last search 31 July 2011). Psychopharmacological studies with the number of participants of ≥ 40 were evaluated in terms of definitions for TRS and subsequent treatment response. Results: Thirty-three studies of antipsychotics in TRS were reviewed. TRS has been defined mainly by severity in symptoms. Many studies based TRS with at least 2 failed adequate antipsychotic trials (at chlorpromazine equivalent doses of ≥ 1000. mg/day for ≥ 6. weeks), but some studies adopted prospective treatment arm to be certain of sample refractoriness. Treatment response has been defined by a relative change in the representative scales (most commonly ≥ 20% decrease in the Positive and Negative Syndrome Scale), but it sometimes included the absolute criteria such as post-treatment score of ≤ 35 in the Brief Psychiatric Rating Scale or Clinical Global Impression-severity score of ≤ 3 (mild or less severe). Social functioning has not been a primary outcome measure in past pivotal trials, and other important domains of the illness such as cognition and subjective perspectives have not been incorporated into definitions of treatment resistance or response. However, adopting various assessment scales can be time-consuming and complicated, with an additional possibility of disagreement among raters. Conclusion: Defining outcomes in schizophrenia is a challenging task. It is imperative that the field agrees on how this population is better defined and what constitutes treatment response.

KW - Definition

KW - Response

KW - Treatment-resistant schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=81955161935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81955161935&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2011.09.016

DO - 10.1016/j.schres.2011.09.016

M3 - Article

C2 - 22000940

AN - SCOPUS:81955161935

VL - 133

SP - 54

EP - 62

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -